Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials
Both Measure Up 1 (n=847) and 2 (n=836) met their co-primary endpoints, showing more patients randomised to treatment with upadacitinib (oral JAK inhibitor; 15mg or 30mg) than placebo achieved an EASI-75 and vIGA-AD response (score of 0 [clear] or 1 [almost clear]) at week 16.
Source:
The Lancet
SPS commentary:
At least a 75% improvement in EASI score from baseline (EASI-75 response) was achieved at week 16 in 70% of the upadacitinib 15mg group, 80% of the upadacitinib 30mg group and 16% of the placebo group in Measure Up 1, and by 60%, 73% and 13%, respectively, in Measure Up 2.
A vIGA-AD response (validated Investigator's Global Assessment for Atopic Dermatitis score of 0 [clear] or 1 [almost clear] with ≥2 grades of reduction from baseline) was achieved at week 16 in 48% of the upadacitinib 15mg group, 62% of the 30mg group and 8% of placebo in Measure Up 1, and in 39%, 52% and 5%, respectively, in the Measure Up 2 study.
The results of the AD Up Phase III study of upadacitinib versus placebo, used in addition topical corticosteroids, in adolescents with moderate to severe atopic dermatitis have been published separately.